Skip to nav Skip to content

Clinical Trial Search

293 Clinical Trials Found

Clinical Trial 20870

Pilot Study to Assess the Efficacy of Aspirin to Improve Immunological Features of Ovarian Tumors
Disease Site: Other Female Genital, Ovary
PI: Chern, Jing-Yi

Clinical Trial 21247

A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK)-Inhibitor
Disease Site: Myeloid and Monocytic Leukemia
PI: Komrokji, Rami

Clinical Trial 20487

Phase I/II Study of Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in the Management of HER2+ Breast Leptomeningeal Disease
Disease Site: Brain and Nervous System, Breast, Leptomeningeal (LMD)
PI: Ahmed, Kamran

Clinical Trial 23142

Precision DC: Personalized Neoantigen Dendritic Cell Vaccine Pilot Trial for High Risk Triple Negative Breast Cancer after Neoadjuvant Therapy
Disease Site: Breast
PI: Soliman, Hatem

Clinical Trial 23154

Disease Site: Other
PI: Sallman, David

Clinical Trial 23177

A Phase 3, Open-Label, Randomized Study of Sonrotoclax(BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia
Disease Site: Chronic Leukemia (CLL, CML), Lymphoid Leukemia
PI: Saeed, Hayder

Clinical Trial 23335

Disease Site: Multiple Myeloma
PI: Nguyen, Nina

Clinical Trial 22325

A Phase 1 Study of Irreversible Electroporation and Pembrolizumab Immunotherapy in Locally Advanced Pancreatic Cancer
Disease Site: Pancreas
PI: Malafa, Mokenge

Clinical Trial 22562

A Multicenter, Open-label, Phase II Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC (Uncommon EGFR Mutations Only)
Disease Site: Lung, Non small cell lung cancer
PI: Gray, Jhanelle

Clinical Trial 21731

A Phase II Trial of Olaparib in Combination with Pembrolizumab for Advanced Uveal Melanoma
Disease Site: Melanoma, skin
PI: Khushalani, Nikhil

Clinical Trial 21416

A Phase 1, Open-label, Preliminary Pharmacokinetics (PK) and Safety Study of CLN-049 (An fms-like tyrosine kinase 3 [FLT3] x cluster of differentiation 3 [CD3] bispecific T cell engager) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
Disease Site: Myeloid and Monocytic Leukemia
PI: Chan, Onyee

Clinical Trial 21854

Disease Site: Lung
PI: Gray, Jhanelle